Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to

DRMA:CommonStockParValue0.0001PerShareMember

DRMA:WarrantsExercisableForOneShareOfCommonStockMember

us-gaap:StockCompensationPlanMember

us-gaap:StockCompensationPlanMember

Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products -

Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle

Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility -

DIEGO, CA, May 13, 2026 - Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) ("Dermata," or the "Company"),

a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the

first quarter ended March 31, 2026.

announcing our strategic pivot in September 2025, we have made meaningful progress toward becoming a direct-to-consumer commercial skincare

company," commented Gerry Proehl, Dermata's Chairman, President, and CEO. "This pivot represents a significant landmark

in our mission to deliver safe, effective, and consumer-friendly skincare products. We continue to build on that foundation during

the first quarter of 2026 by advancing development of our initial product, refining our brand strategy, and aligning our operations

to support commercialization. We are currently finalizing product packaging, putting the finishing touches on the Tome skincare

website and getting ready to initiate consumer use studies to provide clinical data to support our upcoming product launches,"

Mr. Proehl continued. "As we look ahead, we remain focused on executing our planned mid-2026 launch of our once-weekly Foundational

Treatment for skin renewal that we believe will bring an in-office-like treatment into the hands of consumers. We believe this product

launch will position Dermata to deliver long-term value for both consumers and shareholders," concluded Mr. Proehl.

Quarter 2026 Financial Results

of March 31, 2026, the Company had $6.9 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $0.6

million decrease in cash and cash equivalents for the quarter ended March 31, 2026, resulted from approximately $2.0 million of ATM financing

proceeds which were decreased by approximately $0.1 million from equity financing-related expenses, offset by $2.5 million of cash used

in operations. The Company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.

and development expenses were $0.4 million for the quarter ended March 31, 2026, compared to $1.3 million for the quarter ended March

31, 2025. The $0.9 million decrease in research and development expenses was the result of $0.7 million of decreased clinical expenses, $0.1 million of decreased chemistry,

manufacturing and controls, or CMC, and non-clinical expenses, as well as $0.1 million of decreased personnel expenses.

general and administrative expenses were $1.5 million for the quarter ended March 31, 2026, compared to approximately $1.1 million for

the quarter ended March 31, 2025. The increase in selling, general and administrative expenses was primarily attributable to $0.2 million

in marketing expenses incurred, $0.2 million of increased audit fees, and $0.1 million of increased legal fees.

Dermata Therapeutics

Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development

to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing

a first-of-its-kind skin renewal treatment which incorporates Dermata's Bioneedle. The Company plans to launch its initial

product in the middle of 2026 with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more

information, or to join our mailing list, please visit http://www.dermatarx.com/.

is Dermata's new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal

meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in

science and history. Tome will consist of a line of skincare products incorporating its Bioneedle, utilizing Spongilla lacustris,

a wild-harvested, freshwater sponge that has evolved over millions of years, as the primary ingredient for consumers that are

compelled by history and science to find the most potent products for their skincare routine. Dermata believes its Tome skincare line

will simplify existing skincare routines with essential ingredients that deliver results, without harmful extremes. Dermata expects to

launch its first product in the middle of 2026 with additional product launches planned to follow. Start your skincare story at www.tomeskincare.com.

in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's

current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown

risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to

prioritize DTC skincare products; the anticipated benefits of Dermata's strategic shift to prioritize DTC skincare products, including

acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the success,

cost, and timing of the launch of its planned or future DTC products, including the Foundational Treatment; the expected timing

and success of any planned or future DTC product launches; expectations for the success of the Company's products and their ability

to generate revenue for the Company; the Company's expectations with regard to current cash and cash equivalents and the amount

of time it will fund operations; and other factors described in the Company's filings with the Securities and Exchange Commission.

These forward-looking statements are generally identified by the use of such words as "may," "could," "should,"

"would," "believe," "anticipate," "forecast," "estimate," "expect,"

"intend," "plan," "continue," "outlook," "will," "potential"

and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and

expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in

any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization.

For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You

are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is

made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified

in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect

events or circumstances after the date hereof, except as required by law.